CG Oncology, Inc. - 8-K Filing
CG Oncology reported Q1 2026 financial results with a net loss of $60.2 million (or $(0.71) per share), compared to a net loss of $34.5 million in the prior year period, driven by increased R&D and G&A expenses. The company ended March 31, 2026, with $1.1 billion in cash, up from $742.2 million at December 31, 2025, including $391.4 million raised via its ATM facility. It provided business updates on key milestones, including BLA submission for HR BCG-unresponsive NMIBC expected by Q4 2026 and topline data from the PIVOT-006 Phase 3 trial anticipated in H1 2026. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CGON